MHLW Requests Label Changes For Three Drugs
This article was originally published in PharmAsia News
The Food and Drug Safety Department of Japan's Ministry of Health, Labor and Welfare has requested label changes related to warnings for three drugs: BI-Sifrol (pramipexole), a dopaminergic agent for Parkinson's disease made by Nippon Boehringer Ingelheim, Requip (ropinirole) made by GlaxoSmithKline and Endoxan (cyclophosphamide) oral tablet and injection by Shionogi Pharmaceuticals. For Requip and BI-Sifrol, MHLW advised adding warnings related to sudden sleepiness and drowsiness. For Endoxan, the ministry asked for warnings related to liver function disorder, jaundice and acute kidney failure (Click for more-Japanese language
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.